Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Short-term Investments (2016 - 2023)

Ironwood Pharmaceuticals' Short-term Investments history spans 14 years, with the latest figure at $788000.0 for Q3 2023.

  • For Q3 2023, Short-term Investments fell 36.96% year-over-year to $788000.0; the TTM value through Sep 2023 reached $788000.0, down 36.96%, while the annual FY2022 figure was $1.3 million, 0.0% changed from the prior year.
  • Short-term Investments for Q3 2023 was $788000.0 at Ironwood Pharmaceuticals, roughly flat from $788000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $7.9 million in Q3 2021 and bottomed at $788000.0 in Q2 2023.
  • The 5-year median for Short-term Investments is $1.2 million (2019), against an average of $2.3 million.
  • The largest annual shift saw Short-term Investments tumbled 97.48% in 2019 before it surged 352.68% in 2021.
  • A 5-year view of Short-term Investments shows it stood at $1.2 million in 2019, then surged by 38.8% to $1.7 million in 2020, then fell by 25.07% to $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then plummeted by 39.38% to $788000.0 in 2023.
  • Per Business Quant, the three most recent readings for IRWD's Short-term Investments are $788000.0 (Q3 2023), $788000.0 (Q2 2023), and $1.2 million (Q1 2023).